188 related articles for article (PubMed ID: 37471101)
1. Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.
Barbour SJ; Fervenza FC; Induruwage D; Brenchley PE; Rovin B; Hladunewich MA; Reich HN; Lafayette R; Aslam N; Appel GB; Zand L; Kiryluk K; Liu L; Cattran DC;
Clin J Am Soc Nephrol; 2023 Oct; 18(10):1283-1293. PubMed ID: 37471101
[TBL] [Abstract][Full Text] [Related]
2. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
3. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
[TBL] [Abstract][Full Text] [Related]
4. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
PeerJ; 2022; 10():e14193. PubMed ID: 36248712
[TBL] [Abstract][Full Text] [Related]
5. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
[TBL] [Abstract][Full Text] [Related]
6. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y
Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
[TBL] [Abstract][Full Text] [Related]
9. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
Li C; Li H; Wen YB; Li XM; Li XW
BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
[TBL] [Abstract][Full Text] [Related]
10. Combined Serologic and Genetic Risk Score and Prognostication of Phospholipase A2 receptor-Associated Membranous Nephropathy.
Hu X; Xu J; Wang W; Liu L; Jing Y; Gao C; Yu X; Li Y; Lin L; Tong J; Weng Q; Pan X; Zhang W; Ren H; Li G; Kiryluk K; Chen N; Xie J
Clin J Am Soc Nephrol; 2024 May; 19(5):573-582. PubMed ID: 38423528
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
[TBL] [Abstract][Full Text] [Related]
12. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
13. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
[TBL] [Abstract][Full Text] [Related]
14. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.
Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y
Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930
[TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).
Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA
Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329
[TBL] [Abstract][Full Text] [Related]
16. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.
Hoxha E; Thiele I; Zahner G; Panzer U; Harendza S; Stahl RA
J Am Soc Nephrol; 2014 Jun; 25(6):1357-66. PubMed ID: 24610926
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
[TBL] [Abstract][Full Text] [Related]
18. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
[TBL] [Abstract][Full Text] [Related]
19. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients.
Wang B; Zhu Z; Huang F; Huang H; Tu L; Wang Y; Zheng L; Zhou J; Wei X
BMC Nephrol; 2022 Sep; 23(1):306. PubMed ID: 36068486
[TBL] [Abstract][Full Text] [Related]
20. Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
Xiao C; Liu Y; Zhang X; Luo L; Li X; Wang T; Tian Z; Qin X; Liu J
J Clin Lab Anal; 2020 Sep; 34(9):e23368. PubMed ID: 32449206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
